International Biotechnology (IBT) Share Price, News & Analysis

Company Overview

International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of these companies to strategic buyers including major pharmaceutical companies or, in some cases, and through a flotation.

Key Stats

• Today's Range: 667.12 to 680
• 50-Day Range: 666 to 726
• 52-Week Range: 572 to 734
• Volume: 116,841 shs
• Average Volume: 67,767 shs
• Market Capitalization: £250.59 million
• P/E Ratio: 1,412.50
• Dividend Yield: 4.28%
• Price Target: N/A
• Consensus Rating: N/A

IBT Stock Analysis - Frequently Asked Questions

How have IBT shares performed this year?

International Biotechnology's stock was trading at GBX 642 at the beginning of 2024. Since then, IBT shares have increased by 5.6% and is now trading at GBX 678.
View the best growth stocks for 2024 here.

How do I buy shares of International Biotechnology?

Shares of IBT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of International Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that International Biotechnology investors own include Vanquis Banking Group (PFG), 1724525 (ADN.L) (ADN), abrdn New India Investment Trust (ANII), The Berkeley Group (BKG), GLI Finance (GLIF), Hurricane Energy (HUR) and Oxford Pharmascience Group (OXP).

Company Calendar

• Ex-Dividend for 8/23 Dividend: 7/25/2024
• Dividend Payable: 8/23/2024
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Financial Services
• Industry: Asset Management
• Sub-Industry: N/A
• Current Symbol: LON:IBT
• CUSIP: N/A
• CIK: N/A
• Web: www.ibtplc.com
• Phone: 44 20 7421 7070
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX 0.48
• Trailing P/E Ratio: 1,412.50
• Forward P/E Ratio: 718.53
• P/E Growth: N/A
• Net Income: £18.19 million
• Net Margins: 75.33%
• Pretax Margin: N/A
• Return on Equity: 6.25%
• Return on Assets: 3.57%

Debt

• Debt-to-Equity Ratio: 9.66
• Current Ratio: 0.46
• Quick Ratio: 0.32

Sales & Book Value

• Annual Sales: £24.14 million
• Price / Sales: 10.38
• Cash Flow: GBX 4.35 per share
• Price / Cash Flow: 155.74
• Book Value: GBX 749 per share
• Price / Book: 0.91

Miscellaneous

• Outstanding Shares: 36,960,000
• Free Float: N/A
• Market Cap: £250.59 million
• Optionable: Not Optionable
• Beta: 0.21